GlassScriptPhysician profile
Jhonathan Duarte
NPI 1326451188
$2,575.41
in general payments reported to CMS, 2019-2025
24 companies · $835 in 2025
The $835 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $119 · 2021: $388 · 2022: $427 · 2023: $393 · 2024: $175 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,402.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $751.80 | 2019-2025 | Liletta, Lo Loestrin Fe |
| Shield Therapeutics INC | $584.44 | 2023-2025 | Accrufer |
| Evofem Biosciences, INC. | $213.18 | 2022-2025 | Phexxi, Solosec, Phexx |
| Mayne Pharma Commercial LLC | $145.24 | 2022-2025 | |
| Vertical Pharmaceuticals, LLC | $129.52 | 2019-2020 | |
| Hologic Sales and Service, LLC | $116.71 | 2020-2025 | Thinprep 2000 Processor, Aptima, Myosure Tissue Removal Device |
| Coopersurgical, INC. | $70.83 | 2021-2025 | Paragard T 380a, Paragard T 380a |
| Therapeuticsmd, INC. | $60.36 | 2020-2022 | |
| Mission Pharmacal Company | $58.73 | 2019-2021 | |
| Millicent US INC | $54.58 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $48.85 | 2023 | Seglentis |
| Exeltis, USA INC. | $45.30 | 2023-2025 | Slynd |
| Pfizer INC. | $43.01 | 2019-2021 | |
| Organon LLC | $41.94 | 2022-2024 | |
| Avion Pharmaceuticals | $32.92 | 2021-2023 | Balcoltra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30.29 | 2019-2021 | |
| Daiichi Sankyo INC. | $28.25 | 2019-2020 | |
| Organogenesis INC. | $19.96 | 2022 | |
| Scynexis, INC. | $19.69 | 2022 | |
| Becton, Dickinson and Company | $18.81 | 2022 | |
| Axonics, INC. | $18.19 | 2023 | Axonics |
| Duchesnay USA Incorporated | $16.39 | 2019 | |
| Minerva Surgical, INC | $13.62 | 2022 | |
| Ascend Therapeutics US, LLC | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jhonathan Duarte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.